Skye Bioscience Files 8-K: Director Changes & Officer Compensation
Ticker: SKYE · Form: 8-K · Filed: Oct 24, 2024 · CIK: 1516551
Sentiment: neutral
Topics: corporate-governance, executive-compensation, board-changes
TL;DR
Skye Bioscience 8-K: Director shuffle and new pay deal for execs.
AI Summary
Skye Bioscience, Inc. filed an 8-K on October 24, 2024, reporting on the departure of a director, election of a new director, and a compensatory arrangement for a named officer. The filing also covers the submission of matters to a vote of security holders and includes financial statements and exhibits. The report date is October 22, 2024.
Why It Matters
This filing indicates potential shifts in the company's leadership and governance structure, which could impact strategic direction and operational oversight.
Risk Assessment
Risk Level: medium — Changes in directorship and executive compensation can signal internal shifts that may affect future performance or strategy.
Key Players & Entities
- Skye Bioscience, Inc. (company) — Registrant
- October 22, 2024 (date) — Earliest event reported
- October 24, 2024 (date) — Filing date
- Nevada (jurisdiction) — State of incorporation
FAQ
Who departed from the board of directors?
The filing indicates the departure of a director, but the specific name is not provided in the excerpt.
Who was elected to the board of directors?
The filing states the election of a director, but the specific name is not provided in the excerpt.
What is the exact date of the earliest event reported in this 8-K?
The earliest event reported is dated October 22, 2024.
What is the filing date of this 8-K?
This 8-K was filed on October 24, 2024.
What is Skye Bioscience, Inc.'s state of incorporation?
Skye Bioscience, Inc. is incorporated in Nevada.
Filing Stats: 756 words · 3 min read · ~3 pages · Grade level 12.9 · Accepted 2024-10-24 16:59:55
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 SKYE Nasdaq Global Market Indicate
Filing Documents
- skye-20241022.htm (8-K) — 36KB
- 0001516551-24-000091.txt ( ) — 158KB
- skye-20241022.xsd (EX-101.SCH) — 2KB
- skye-20241022_def.xml (EX-101.DEF) — 2KB
- skye-20241022_lab.xml (EX-101.LAB) — 21KB
- skye-20241022_pre.xml (EX-101.PRE) — 12KB
- skye-20241022_htm.xml (XML) — 2KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders At the Special Meeting, holders of 23,686,215 shares of the Company's Common Stock were present in person or represented by proxy, constituting a quorum. The following are the voting results of the proposal to approve the Amended and Restated Plan that was presented to the Company's stockholders at the Special Meeting: Votes For Votes Against Abstentions 17,444,443 6,228,672 13,100
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Skye Bioscience, Inc. Amended and Restated Omnibus Incentive Plan (incorporated by reference to Appen dix A to the Company's Definitive Proxy Statement on Schedule 14A, filed with the Securities and Exchange Commission on September 23, 2024) 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SKYE BIOSCIENCE, INC. Dated: October 23, 2024 /s/ Punit Dhillon Name: Punit Dhillon Title: Chief Executive Officer